Table 2.
Patient scores for the assessment of CIPN and physical performance.
| Variable/Measure (Unit) | Baseline | Post Phase 1 | Post Phase 2 | Post Phase 3 |
|---|---|---|---|---|
| PainDETECT Score | 27 | 24 | 26 | 18 |
| FACT-GOG-Ntx Score | 37 | 34 | 44 | 48 |
| FACT-GOG-Ntx TOI Score | 74 | 78 | 84 | 93 |
| FACT-GOG Total Score | 67 | 77 | 73 | 81.3 |
| GSLPA Score | 22 | 30 | 40 | 46 |
| GS (m/s) | 0.91 | 1.00 | 1.08 | 1.16 |
| 5× STS (seconds) | 14.65 | 9.8 | 11.09 | 10.69 |
| HGS (kg) | 27 | 28 | 29 | 30 |
| 9-HPT (seconds) | 19.3 | 17.8 | 18.34 | 16 |
FACT-GOG-Ntx: Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (CIPN symptoms) subscale; FACT-GOG-Ntx TOI: FACT-GOG-Ntx Trial Outcome Index (perceived physical function, pPF); GSLPA: Godin-Shephard leisure-time physical activity; GS: Gait speed (mobility); 5× STS: 5 times Sit to Stand (lower body strength); HGS: hand grip strength (handheld dynamometer, upper body strength); 9-HPT: 9-Hole Peg Test (finger/hand dexterity).